Abstract
Background: Severe coronavirus disease-2019 (COVID-19) can progress to an acute respiratory distress syndrome (ARDS), which involves alveolar infiltration by activated neutrophils. The beta-blocker metoprolol has been shown to ameliorate exacerbated inflammation in the myocardial infarction setting.
Objectives: The purpose of this study was to evaluate the effects of metoprolol on alveolar inflammation and on respiratory function in patients with COVID-19-associated ARDS.
Methods: A total of 20 COVID-19 patients with ARDS on invasive mechanical ventilation were randomized to metoprolol (15 mg daily for 3 days) or control (no treatment). All patients underwent bronchoalveolar lavage (BAL) before and after metoprolol/control. The safety of metoprolol administration was evaluated by invasive hemodynamic and electrocardiogram monitoring and echocardiography.
Results: Metoprolol administration was without side effects. At baseline, neutrophil content in BAL did not differ between groups. Conversely, patients randomized to metoprolol had significantly fewer neutrophils in BAL on day 4 (median: 14.3 neutrophils/µl [Q1, Q3: 4.63, 265 neutrophils/µl] vs median: 397 neutrophils/µl [Q1, Q3: 222, 1,346 neutrophils/µl] in the metoprolol and control groups, respectively; P = 0.016). Metoprolol also reduced neutrophil extracellular traps content and other markers of lung inflammation. Oxygenation (PaO 2 :FiO 2 ) significantly improved after 3 days of metoprolol treatment (median: 130 [Q1, Q3: 110, 162] vs median: 267 [Q1, Q3: 199, 298] at baseline and day 4, respectively; P = 0.003), whereas it remained unchanged in control subjects. Metoprolol-treated patients spent fewer days on invasive mechanical ventilation than those in the control group (15.5 ± 7.6 vs 21.9 ± 12.6 days; P = 0.17).
Conclusions: In this pilot trial, intravenous metoprolol administration to patients with COVID-19-associated ARDS was safe, reduced exacerbated lung inflammation, and improved oxygenation. Repurposing metoprolol for COVID-19-associated ARDS appears to be a safe and inexpensive strategy that can alleviate the burden of the COVID-19 pandemic.
Keywords: ARDS; COVID; acute care; metoprolol.
【저자키워드】 ARDS, COVID, acute care, metoprolol., metoprolol, 【초록키워드】 COVID-19, Treatment, Inflammation, coronavirus, Trial, Respiratory function, COVID-19 pandemic, neutrophil, repurposing, Randomized, BAL, Patient, Neutrophil extracellular trap, Myocardial infarction, Side effects, acute respiratory distress, marker, hemodynamic, Activated neutrophils, Bronchoalveolar lavage, infiltration, Invasive mechanical ventilation, administration, Lung inflammation, COVID-19 patient, Safe, Oxygenation, intravenous, control group, control subjects, syndrome, control groups, alveolar, invasive, COVID-19-associated ARDS, alveolar inflammation, not differ, shown, significantly, remained, evaluated, exacerbated, reduced, appear, groups, evaluate the effect, alleviate, baseline, PaO, patients randomized, 【제목키워드】 COVID-19, Ill,